Abstract Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common liver disease, with a global prevalence estimated up to 7.5% and substantial concern for hepatic and extrahepatic complications even in early life. In this paper, we review recent advances in epidemiology, genetics, early-life risk factors, natural history and comorbidities, focusing on emerging data published in the last 3 years. We also outline a practical approach to the management of MASLD in children, integrating newly developed non-invasive tests. Lastly, we provide key research questions to be studied in the coming years.
Lefere et al. (2026) studied this question.